Acetyl Hexapeptide-3 (Argireline) inhibits the release of neurotransmitters as it interferes with the formation and stabilization of the protein complex needed for docking vesicles of acetylcholine release. In an open study often female subjects, a serum containing this peptide was applied twice a day. After 1 month, the results showed a reduction in periorbital wrinkle depth of 27%. The in vitro effect of neurotransmitter-inhibiting peptides is to inhibit the release of neurotransmitters, while the desired, in vivo, effect is to reduce facial wrinkles caused by a decrease in muscle activity. Research tests were performed using a combination of both actives in order to evaluate a possible synergy or additive effect. A cream/serum containing 5% argireline solution (0.05%) and 5% leuphasyl solution (0.05%) was applied twice daily around the eyes of 15 volunteers, aged 39 to 63, for 28 days. A decrease of 24.62% was accomplished, with maximum values up to –46.53%. Both peptides show additive effects due to their complementary mechanisms.
Ipamorelin (5mg x 10), CJC-1295 no DAC (5mg x 10)
Original price was: $955.00.$811.00Current price is: $811.00.
Adipotide (FTPP) 10mg
$89.00
New
Acetyl Hexapeptide-3 (Argireline) 200mg (Topical)
$220.00
Acetyl Hexapeptide-3 (Argireline) inhibits the release of neurotransmitters as it interferes with the formation and stabilization of the protein complex needed for docking vesicles of acetylcholine release.
Description
Shipping & Delivery
Related products
OS-01 (100mg x 30 Capsules)
OS-01 is an AMP-activated protein kinase (AMPK) activator that modulates cellular energy homeostasis and metabolic function. AMPK, a central regulator of energy balance, is activated in response to low intracellular ATP levels, enhancing glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. OS-01 stimulates AMPK phosphorylation, leading to increased ATP production, improved insulin sensitivity, and enhanced autophagic flux, thereby promoting cellular repair and longevity. This compound has been shown to mitigate oxidative stress by downregulating reactive oxygen species (ROS) and inflammatory cytokines, reducing cellular damage and aging-related dysfunction. Additionally, OS-01 enhances endurance by optimizing energy substrate utilization and preserving glycogen stores during exercise. It plays a protective role in renal and cardiovascular systems by attenuating fibrosis, reducing endothelial dysfunction, and improving mitochondrial efficiency. Preclinical studies suggest its potential in managing metabolic disorders, including type 2 diabetes, obesity, and cardiovascular diseases, by improving glucose homeostasis and reducing insulin resistance. Furthermore, OS-01’s activation of autophagy contributes to neuroprotection, reducing age-related neurodegeneration. Its multifaceted mechanism positions it as a promising candidate for therapeutic intervention in metabolic and age-related diseases.
Semaglutide
Semaglutide is a widely researched peptide-based compound recognized for its significant role in metabolic regulation and appetite control. It belongs to the class of GLP-1 receptor agonists, which are designed to mimic naturally occurring hormones involved in glucose metabolism and satiety signaling.
SLU-PP-332
SLU-PP-332 (250mcg x 60 Capsules = 15,000mcg) SLU-PP-332 (1000mcg x 30 Capsules = 30,000mcg) SLU-PP-332 is an experimental compound designed to mimic the metabolic effects of exercise by activating estrogen-related receptors (ERRs), particularly ERRα, ERRβ, and ERRγ. This activation leads to increased energy expenditure, enhanced fatty acid oxidation, and improved mitochondrial function.
Reviews
There are no reviews yet.